A new functional classification of tumor-suppressing genes and its therapeutic implications

BioEssays

Volumn 22, Issue 3, 2000, Pages 274-285

  Islam, M Quamrul ^a   Islam, Khaleda ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; CELL FUSION; CELL GROWTH; GENE DOSAGE; GENE MUTATION; GENE THERAPY; GENETIC DIFFERENCE; GROWTH INHIBITION; HOMOZYGOSITY; PHENOTYPE; RECESSIVE INHERITANCE; TUMOR SUPPRESSOR GENE; WILD RELATIVE;

ANIMALS; GENES, TUMOR SUPPRESSOR; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASM PROTEINS; NEOPLASMS;

EID: 0034013929     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-1878(200003)22:3<274::AID-BIES9>3.0.CO;2-G     Document Type: Review

References (90)

1. Harris H, Miller OJ, Klein G, Worst P, Tachibana T. Suppression of malignancy by cell fusion. Nature 1969;223:363-368.
2. Marshall CJ. Tumor suppressor genes. Cell 1991;64:313-326.
3. Stanbridge EJ. Human tumor suppressor genes. Annu Rev Genet 1990;24:615-657.
4. Stanbridge EJ, Wilkinson J. Analysis of malignancy in human cells: malignant and transformed phenotypes are under separate genetic control. Proc Natl Acad Sci USA 1978;75:1466-1469.
5. Islam MQ, Islam K, Levan G, Horvath G. Monochromosome transfers to Syrian hamster BHK cells via microcell fusion provide functional evidence for suppressor genes on human chromosome 9 both for anchorage independence and for tumorigenicity. Genes Chrom Cancer 1995;13:115-125.
6. Knuoson Jr AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-823.
7. Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997;278:1043-1050.
8. Haber D, Harlow E. Tumor-suppressor genes: evolving definitions in the genomic age. Nat Genet 1997;16:320-322.
9. Harris H. The analysis of malignancy by cell fusion: the position in 1988. Cancer Res 1988;48:3302-3306.
10. Harris H. How tumor suppressor genes were discovered. FASEB J 1993;7:978-979.
11. Lin S-CJ, Skapek SX, Lee Y-HP. Genes in the RB pathway and their knockout in mice. Cancer Biol 1996;7:279-289.
12. Jacks T. Tumor suppressor gene mutations in mice. Annu Rev Gent 1996;30:603-636.
13. McClatchey AI, Jacks T. Tumor suppressor mutations in mice: the next generation. Curr Opinion Genet Dev 1998;8:304-310.
14. Donehower LA. The p53-deficient mouse: a model for basic and applied cancer studies. Cancer Biol 1996;7:269-278.
15. Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biol Sci 1998;23: 291-296.
16. McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, Bronson RT, Jacks T. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 1998;12:1121-1133.
17. Hahn H, Wojnowski L, Zimmer AM, Hall J, Miller G, Zimmer A, Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorline syndrome. Nat Med 1998;4:619-622.
18. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumor suppression. Nat Genet 1998; 19:348-355.
19. Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 1998;12:2899-2911.
20. Schreiber-Agus N, Meng Y, Hoang T, Hou H Jr, Chen K, Greenberg R, Cordon-Cardo C, Lee H-W, DePinho RA. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature 1998;393:483-487.
21. Foley KP, McArthur GA, Queva C, Hurlin PJ, Soriano P, Eisenman RN. Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation. EMBO J 1998;17:774-785.
22. Bignon Y-J, Chen Y, Chang C-Y, Riley DJ, Windle JJ, Mellon PL, Lee W-H. Expression of a retinoblastoma transgene results in dwarf mice. Genes Dev 1993;7:1654-1662.
23. Godley LA, Kopp JB, Eckhaus M, Paglino JJ, Owens J, Varmus HE. Wildtype p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys. Genes Dev 1996;10:836-850.
24. Wu H, Wade M, Krall L, Grisham J, Xiong Y, Van Dyke T. Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development, and regeneration. Genes Dev 1996;10:245-260.
25. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C. Mice lacking cyclin D1 are smal and show defects in eye and mammary gland development. Genes Dev 1995;9:2364-2372.
26. Rubles AI, Rodriguez-Puebla ML, Click AB, Trempus C, Hansen L, Sicinski P, Tennant RW, Weinberg RA, Yuspa SH, Conti CJ. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 1998;12:2469-2474.
27. Hunter T. Cooperation between oncogenes. Cell 1991;64:249-270.
28. Knudson AG Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985;45:1437-1443.
29. Bischoff FZ, Strong LC, Yim SO, Pratt DR, Siciliano MJ, Giovanella BC, Tainskey MA. Tumorigenic transformation of spontaneously immortalized fibroblasts from patients with a familial cancer syndrome Oncogene 1991;6:183-186.
30. INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 1995;15:4745-4753.
31. Boukamp P, Popp S, Altmeyer S, Hulsen A, Fasching C, Cremer T, Fusenig NE. Sustained nontumorigenic phenotype correlates with a largely stable chromosome content during long-term culture of the human keratinocyte line HaCaT. Genes Chrom Cancer 1997;19: 201-214.
32. Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, Giovanella BC, Tainsky MA, Bradley A, Donehower LA. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 1993;8:2457-2467.
33. Yahanda AM, Bruner JM, Donehower LA, Morrison R. Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol Cell Biol 1995;15: 4249-4259.
34. Benedict WF, Banerjee A, Mark C Murphee AL. Nonrandom chromosomal changes in untreated retinoblastomas. Cancer Genet Cytogenet 1933;10:311-333.
35. Williams BO, Schmitt EM, Remington L, Bronson RT, Albert DM, Weinberg RA, Jacks T. Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J 1994;13:4251-4259.
36. Maandag ECR, van der Valk M, Vlaar M, Feltkamp C, O'Brien J, van Roon M, van der lugt N, Berns A, te Riele H. Developmental rescue of an embryonic-lethal mutation in the retinoblastoma gene in chimeric mice. EMBO J 1994;13:4260-4268.
37. Zhou Y, Li J, Xu K, Hu S-X, Benedict WF, Xu H-J. Further characterization of retinoblastoma gene-mediated cell growth and tumor suppression in human cancer cells. Proc Natl Acad Sci USA 1994;91:4165-4169.
38. Wang JYJ, Knudsen ES, Welch PJ. The retinoblastoma tumor suppressor protein. Adv Cancer Res 1994;64:25-85.
39. Saxon PJ, Srivatsan ER, Stanbridge EJ. Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. EMBO J 1986;5:3461-3466.
40. Bader SA, Fasching C, Brodeur GM, Stanbridge EJ. Dissociation of suppression of tumorigenicity and differentiation in vitro effected by transfer of single human chromosomes into human neuroblastoma cells. Cell Growth Diff 1991;2:245-255.
41. Imreh S, Kost-Alimova M, Kholodnyuk I, Yang Y, Szeles A, Kiss H, Liu Y, Foster K, Zabarovsky E, Stanbridge E, Klein G. Differential elimination of 3p and retention of 3q segments in human/mouse microcell hybrids during tumor growth. Genes Chrom Cancer 1997;20:224-233.
42. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-852.
43. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for irradiation-induced apoptosis in mouse thymocytes. Nature 1993;362:447-449.
44. Bouffler SD, Kemp CJ, Balmain A, Cox R. Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice. Cancer Res 1995;55:3883-3889.
45. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA. Retention of wild-type p53 in tumors from p53 heterozygous mice reduction of p53 dosage can promote cancer formation. EMBO J 1998;17:4657-4667.
46. RB, the retinoblastoma tumor suppressor protein. Oncogene 1995;10:697-704.
47. Pagliaro LC, Antelman D, Johnson DE, Machemer T, McCulloch EA, Freireich EJ, Stass SA, Shepard HM, Maneval D, Gutterman JU. Recombinant human retinoblastoma protein inhibits cancer cell growth. Cell Growth Diff 1995;6:673-680.
48. WAF1. Curr Biol 1996;7:71-80.
49. WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res 1997;57:1442-1446.
50. kip 1 is haplo-insufficient for tumor suppression. Nature 1998;396: 177-180.
51. Walker GJ, Flores JF, Glendening JM, Lin A, Markl IDC, Fountain J. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chrom Cancer 1998;22:157-163.
52. CDKN2/INK4A. Curr Biol 1995;6:84-91.
53. Fåhraeus R, Lain S, Ball KL, Lane DP. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumor suppressor molecule. Oncogene 1998;16: 587-596.
54. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1997;1332:F127-F147.
55. Tang B, Böttinger EP, Jakowlew SB, Bagnall KM, Mariano J, Anver MR, Letterio JJ, Wakefield LM: Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 1998;4: 802-807.
56. Yeung RS, Xiao GH, Everitt JI, Jin F, Walker CL. Allelic loss at the tuberous sclerosis 2 locus in spontaneous tumors in the Eker rat. Mol Carcinog 1995;14:28-36.
57. Nachtigal MW, Hirokawa Y, Enyeart-VanHouten DL, Flanagan JN, Hammer GD, Ingraham HA. Wilms' tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. Cell 1998;93:445-454.
58. Evans EP, Burtenshaw MD, Brown BB, Hennion R, Harns H. The analysis of malignancy by cell fusion. IX. Re-examination and clarification of the cytogenetic problem. J Cell Sci 1982;56:113-130.
59. Benedict WF, Weissman BE, Mark C, Stanbridge EJ. Tumorigenicity of human HT1080 fibrosarcoma X normal fibroblast hybrids: chromosome dosage dependency. Cancer Res 1984;44.3471-3479.
60. Anderson MJ, Casey G, Fasching CL, Stanbridge EJ. Evidence that wild-type TP53, and not genes on either chromosome 1 or 11, controls the tumorigenic phenotype of the human fibrosarcoma HT1080. Genes Chromosome Cancer 1994;9:266-281.
61. Harris H. The role of differentiation in the suppression of malignancy. J Cell Sci 1990;97:5-10.
62. Sager R. Senescence as a mode of tumor suppression. Environ Health Perspect 1991;93:59-62
63. Ning Y, Shay JW, Lovell M, Taylor L, Ledbetter DH, Pereira-Smith O. Tumor suppression by chromosome 11 is not due to cellular senescence. Exp Cell Res 1991;192:220-226.
64. Aso T, Haque D, Barstead RJ, Conaway RC, Conaway JW. The inducible elongin A elongation activation domain: structure, function and interaction with the elongin BC complex. EMBO J 1995;15:5557-5566.
65. Krumm A, Groudine M. Tumor suppression and transcription elongation: the dire consequences of changing partners. Science 1995;269: 1400-1401.
66. Bouchard C, Staller P, Eilers M. Control of cell proliferation by Myc. Trends Cell Biol 1998;8:202-206.
67. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995;80:285-291.
68. Farrow SN, Brown R. New members of the Bcl-2 family and their partners. Curr Opi Genet Dev 1996;6:45-49.
69. INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res 1995;55:4818-4823.
70. INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-99.
71. Soufir N, Avril M-F, Chompret A, Demenais F, Bombled J. Spatz A, Stoppa-Lyonnet D, Paillerets BB. The French Familial Melanoma Study Group, Bernard J. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 1998;7:209-216.
72. CIP1 and Cdc25A: competition between an inhibitor and an activator of cyclin-dependent kinases. Mol Cell Biol 1997;17:4338-4345.
73. Hastie N. Disomy and disease resolved? Nature 1997;389:785-786.
74. Rey I, Hall A. Tumor suppressors and the regulation of GTP-binding protein activity. Trends Cell Biol 1993;3:39-42.
75. Ingham PW. Transducing hedgehog: the story so far. EMBO J 1998;17: 3505-3511.
76. Ben-Ze'ev A, Geiger B. Differential molecular interactions of β-catenin and plakoglobin in adhesion, signaling and cancer. Curr Opinion Cell Biol 1998;10:629-639.
77. Heldin CH, Miyazono K, ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-471.
78. Robertson K, Mason I. The GDNF-RET signalling partnership. Trends Genet 1997;13:1-3.
79. Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 1996;122:135-140.
80. Jansen-Durr P. How viral oncogenes make the cell cycle. Trends Genet 1996;12:270-275.
81. Funk JO, Galloway DA. Inhibiting CDK inhibitors: new lessons from DNA tumor viruses. Trends Biol Sci 1998;23:337-341.
82. INK4 gene mediated by an adenovirus vector. Cancer Res 1995;55:3250-3253.
83. Yang C, Cirielli C, Capogrossi MC, Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostate tumor cells. Cancer Res 1995;55: 4210-4213.
84. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WKA. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 1996;56:694-699.
85. Cirielli C, Riccioni T, Yang C, Pili R, Gloe T, Chang J, Inyaku K, Passaniti A, Capogrossi MC. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. Int J Cancer 1995;63:673-679.
86. KIP1 overexpression causes apoptotic death of mammalian cells. Oncogene 1997;15: 2991-2997.
87. Sekiguchi T, Hunter T. Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHK21 cells. Oncogene 1998;16:369-380.
88. Islam MQ, Islam K. Lack of tumor suppression but induced loss of copies of indigenous chromosome 10 in vitro following microcell-mediated transfer of a deleted human der(9)t(X;9) chromosome to BHK-191-5C cells. Cytogenet Cell Genet 1999;87:11-18.
89. Islam MQ, Islam K. Evidence for suppression of cellular growth in vitro and selection against the indigenous mouse X chromosome in A9 cell hybrids after microcell-mediated transfer of an X from other mammalian species. Cytogenet Cell Genet 2000; in press.
90. Islam MQ, Islam K, Suppressor genes for malignant and anchorage independent phenotypes located on human chromosome 9 have no dosage effects. Cytogenet Cell Genet 2000; in press.